2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry index, is up by nearly 13% year to date.
Still, it's too early to say whether the industry will keep up this momentum all year long; we are only in March. But no matter what happens to this sector, let's consider two biotech stocks worth buying and holding on to for a while: Regeneron Pharmaceuticals (NASDAQ: REGN) and Exelixis (NASDAQ: EXEL).
Source Fool.com
Regeneron Pharmaceuticals Inc. Aktie
1.021,0 €
-1,50 %
Die Regeneron Pharmaceuticals Inc. Aktie zieht viel Aufmerksamkeit auf sich: Viel mehr Buy- als Sell-Einschätzungen.
Ein Kursziel von 1085 € für Regeneron Pharmaceuticals Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 1021.0 €.
